All In Biotech

Drug Trial Radar · NCT07588906

To Compare the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability Between SHR-3167 Injection and Glargine Insulin in Healthy Subjects

A Phase I Clinical Trial of the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of a Single Subcutaneous Injection of SHR-3167 Injection and Glargine Insulin in Healthy Subjects

Last checked: Nov 19, 2026Latest source record: May 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

24

Actual

Start

Feb 26, 2024

Primary completion

Jul 12, 2024

Study completion Jul 23, 2024

Sponsor

Sponsor type
Industry
First posted
May 15, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Male only, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the pharmacodynamic profile of a single subcutaneous dose of SHR-3167 injection versus insulin glargine U100 in healthy subjects.

Conditions

  • Healthy Subjects

Interventions

  • SHR-3167 injection;glargine insulinDrug

    Drug: SHR-3167 injection Participants will receive a single subcutaneous (s.c.) injections of SHR-3167 injection Drug: glargine insulin Participants will receive a single subcutaneous (s.c.) injections of glargine insulin

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Glucose infusion rate (GIR) - area under the curve (AUC)Time frame: Glargine period: 0-24hour ; SHR-3167 period: 0-226hour

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Bishan Hospital of Chongqing

    Chongqing, Chongqing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.